Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | HCK | P08631 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.34 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.34 |
| ▸ | PRKDC | P78527 | 2/20 | 0.34 |
| ▸ | QPCT | Q16769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26967225 | 0.98 | PIK3C3 (0.40) | PIK3C3DYRK1AKEAP1SSTR4NAMPT | |
| SCHEMBL30186393 | 0.80 | HSD17B2 (0.47) | PIK3C3CYP1A2PIK3CA | |
| SCHEMBL31380997 | 0.79 | PIK3C3 (0.49) | PIK3C3DYRK1AMEN1KMT2APIK3CD | |
| SCHEMBL3185174 | 0.78 | PIK3C3 (0.38) | PIK3C3DYRK1AKEAP1SSTR4NAMPT | |
| SCHEMBL174229 | 0.74 | DYRK1A (0.43) | PIK3C3DYRK1AKEAP1SSTR4NAMPT | |
| SCHEMBL14144231 | 0.74 | PIK3C3 (0.38) | PIK3C3DYRK1AKEAP1SSTR4NAMPT | |
| SCHEMBL557143 | 0.74 | SMN1; SMN2 (0.44) | PIK3C3KEAP1KMT2ACYP1A2PIK3CD | |
| SCHEMBL557352 | 0.74 | EGLN2 (0.39) | PIK3C3DYRK1AKEAP1SSTR4NAMPT | |
| SCHEMBL20755769 | 0.74 | PIK3C3 (0.38) | PIK3C3DYRK1AKEAP1SSTR4NAMPT | |
| SCHEMBL18554370 | 0.74 | OGA (0.39) | PIK3C3DYRK1AKEAP1SSTR4NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267320-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2022-08-25 | — | — | US | claimed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | claimed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | claimed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | claimed |
| EP-3806853-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | ONCO3R THERAPEUTICS BV (BE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4658659-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12447153-B2 | HER2 mutation inhibitors | PFIZER INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250276983-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-4577549-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | Iambic Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250154144-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDRENS HOSPITAL MED CT (US) | 2025-05-15 | — | — | US | disclosed |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2025-04-01 | — | — | US | disclosed |
| CN-119661537-A | Nucleoside compound, preparation method thereof, composition thereof and application of nucleoside compound in medicine | 中国科学院上海药物研究所 | 2025-03-21 | — | — | CN | disclosed |
| US-8722687-B2 | Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy | ASTEX THERAPEUTICS LTD (GB) | 2014-05-13 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| EP-2419428-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | Astex Therapeutics Ltd. (GB) | 2012-02-22 | — | — | EP | disclosed |
| US-20120041000-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010119285-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2007059257-A2 | N4-PHENYL-QUINAZ0LINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041000-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | FGFR1, FGFR3, FGFR2 | PIK3C3 788/4885DYRK1A 482/4885KEAP1 1412/4885 |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | TNF, IL1A, COL1A1 | PIK3C3 394/4885DYRK1A 2742/4885KEAP1 1606/4885 |
| US-20220267320-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | NCOA3, NCOR1, NCOA4 | PIK3C3 1080/4885DYRK1A 1765/4885KEAP1 832/4885 |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | PIK3C3 107/4885DYRK1A 1291/4885KEAP1 2612/4885 |
| US-20250154144-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK3 | PIK3C3 70/4885DYRK1A 694/4885KEAP1 1194/4885 |
| US-12447153-B2 | HER2 mutation inhibitors | ERBB2, EGFR, ERBB3 | PIK3C3 697/4885DYRK1A 166/4885KEAP1 943/4885 |
| US-20250276983-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | ERBB2, EGFR, ERBB3 | PIK3C3 2874/4885DYRK1A 54/4885KEAP1 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.